<DOC>
	<DOCNO>NCT01442337</DOCNO>
	<brief_summary>The purpose study evaluate efficacy , safety tolerability single intravenous dose ASP8597 kidney transplant recipient .</brief_summary>
	<brief_title>A Study Evaluate Effect ASP8597 Adult Kidney Transplant Patients</brief_title>
	<detailed_description>This two-part study . Part 1 ( Phase 2 ) complete enrollment . Subjects currently follow per protocol . Data Part 1 use determine dos use Part 2 ( Phase 3 ) . Part 2 enroll approximately 573 subject plan 2 dos ASP8597 ( low dose either high high dose ) along placebo .</detailed_description>
	<criteria>Subject schedule receive kidney transplant decease donor meeting least one follow criterion : 1 . Expanded Criteria Donor ( ECD ) Donor &gt; 60 year age , OR ii . Donor 5059 year age , inclusive , meet least two follow criterion : 1 . Donor die cerebral bleed 2 . Donor history hypertension 3 . Donor 's terminal serum creatinine concentration &gt; 1.5 mg/dL 2 . Donation Cardiac Death ( DCD ) Donor pronounce dead prior procurement kidney 3 . Standard Criteria Donor ( SCD ) i. Donor terminal serum creatinine &lt; 1.5 mg/dL kidney anticipate minimum 24 hour cold ischemia prior transplantation , OR ii . Donor terminal serum creatinine &gt; 1.5 mg/dL cold ischemic time exclusion limit Female subject pregnant agree use acceptable form contraception throughout study Male subject agree use adequate method contraception agree sperm donation throughout study Female subject pregnant lactating Donor kidney anticipate 40 hour cold ischemia time Donor &gt; 66 year age Donor meet DCD ECD criterion Subject previously receive , receive organ transplant kidney Subject positive T B cell crossmatch investigational site 's standard method determination . For recipient flow cytometry crossmatch perform positive either T B cell testing , recipient exclude donor specific , antiHLA antibody detect flow cytometry base , specific antiHLA antibody test Subject ABO blood type incompatibility his/her organ donor Recipient donor know medical history seropositive human immunodeficiency virus ( HIV ) Subject know bleed diathesis Subject International Normalized Ratio ( INR ) &gt; 1.5 time upper limit normal Screening Subject platelet count &lt; 100,000 platelets/µL Screening Subject use antiplatelet agent [ e.g. , Plavix® ( clopidogrel bisulfate ) , Brilinta® ( ticagrelor ) ] ( exception aspirin &lt; 100 mg/day cardiovascular prophylaxis ) , anticoagulant [ e.g. , Pradaxa® ( dabigatran ) , Xarelto® ( rivaroxaban ) ] , antithrombotics , and/or bloodthinning agent within 10 day prior Screening ; and/or subject expect require use agent first 15 day study period ( exception standard care perioperative administration heparin DVT prophylaxis ) Subject uncontrolled concomitant infection Subject current malignancy history malignancy ( within past 5 year ) , except nonmetastatic basal squamous cell carcinoma skin treat successfully Subject currently participate investigational drug study , participate investigational drug study within last 30 day ) Subject history believe used illicit drug ( ) and/or abuse alcohol within last 3 month Subject unstable psychiatric illness Subject previously receive ASP8597 participate study involve ASP8597</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>70 Years</maximum_age>
	<verification_date>June 2014</verification_date>
	<keyword>de novo kidney transplant</keyword>
	<keyword>kidney transplant</keyword>
	<keyword>ASP8597</keyword>
	<keyword>diannexin</keyword>
	<keyword>ischemia-reperfusion injury</keyword>
</DOC>